... a way to identify patients who may benefit from treatment with tiromeprajie inhibitors.

摘要

There are no mutations in JAK 2, calr and MPL, and / or asxl 1, Ezh 2 Based on the presence of at least one mutation in the genetic genes of srsf 2 and IDH 1 / 2, high molecular risk (HMR) trials, such as steroid inhibitors such as e-metel start, can provide the most beneficial method for patient identification or selection.The patient will have myelofibrosis.This initiation also provides a method for the treatment of myelofibrosis including patient confirmation.